News Room

Press Release

  • 12 May 2020

    Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India. These countries consist of nearly all low-income and lower middle-income countries, as well as several upper-middle and high-income countries that face significant obstacles to healthcare access. Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries.

    Commenting on the partnership, Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Limited, said, “We are very happy to strengthen our partnership with Gilead to license remdesivir, which, based on initial data, shows promise to be a potential therapy for Covid-19, a pandemic creating unprecedented health and economic crisis globally. We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s Active Pharmaceutical Ingredient (“API”) in-house helping its cost effectiveness and consistent availability.”

    Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by USFDA to treat Covid-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease. The EUA is based on available data from two global clinical trials – US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead’s global Phase 3 study evaluating remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of remdesivir as a treatment for COVID-19. Remdesivir remains an investigational drug and has not been approved by USFDA.

  • 16 April 2020

    Press Statement

    Jubilant Life Sciences Limited noted in a press statement today that no traces of COVID-19 virus have been found in the imported Raw Material sampled from Nanjangud facility of its subsidiary - Jubilant Generics Limited. Raw Material (imported from China) tested negative for COVID-19 virus by National Institute of Virology, Pune as announced by the authorities of Government of Karnataka.

    It is unfortunate that a wrong perception was created in public and media about the Raw Material imported from China.

    Additionally, the Company clarified that Patient P52 did not travel to China or on any overseas trip in the last six months. Further, none of the employees tested positive so far travelled overseas in the last six months.

    Jubilant Generics Limited at its plant located at Nanjangud, Mysore manufactures Active Pharmaceutical Ingredients used in drugs that are needed for sustaining patients' lives, including Azithromycin Dihydrate and Azithromycin Monohydrate, which are needed to fight the global menace of COVID-19.

    All evidences and known scientific facts published by reputed global organisations, available so far, indicates that the virus does not survive for more than 72hours on any surface. The Raw Materials sampled from the Nanjangud facility had taken more than three weeks (>21days) of transit to reach the plant by Sea Route and no virus can survive this long on any surface.

    In any case, Patient P52, the first positive case of COVID-19 from the Nanjangud facility, never had any contact with any raw material nor had role in Receiving, Transporting, Handling or Storage of raw materials.

    Jubilant values the health and safety of employees and community in and around its facility. It is continuously working towards ensuring that all their needs are met and necessary precautionary measures as directed by Government protocols are being followed.

    The Company values the support it has received from all levels of Government authorities including District administration, Police, Public health department and the community around its facility. Jubilant is constantly communicating and working with them to mitigate the situation arising of the COVID-19.

  • 04 April 2020

    Jubilant Life Sciences supports distribution of health and safety material in Karnataka

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, said, that it is providing support to Government of Karnataka’s efforts in delivering effective health and safety services to manage COVID-19 crisis.

    The Company spokesperson said, “At Jubilant Life Sciences we value the health and safety of our community and employees. We are continuously working towards ensuring that all their needs are met, taking necessary precautionary measures as well as following government directed protocols. We are also working closely with the district and state administration officials and are extending all necessary support for mitigating COVID-19 crisis.”

    The Company has distributed over 7,000 masks and around 325 litres of sanitizers to policy makers, health and administrative staff within the state of Karnataka. Furthermore, some of the daily wage workers are being supported through various networks to ensure access to food, masks and soaps. To draw awareness and help citizens understand the gravity of the situation, the Company has initiated educational drives across multiple locations, focusing on the importance of social distancing, sanitization and overall hygiene.

    As a precautionary measure, the Nanjangud plant operations have been temporarily suspended and all the personnel are under self-quarantine. The Company has proactively engaged an external certified agency for disinfection and has completed the disinfection process for all the plant areas to make the workplace safe and healthy.

    The Company has distributed over 5,000 masks, 200 litres of sanitizers, essential food items, water and medical facilities to employees and their extended families.

    Jubilant Life Sciences has contributed a sum of Rupees 25 lakhs towards the CM Relief Fund to support the Government’s efforts to combat the spread of COVID-19.

  • 13 February 2020

    Jubilant Receives Favorable Rulings from the U.S. Patent Office Invalidating Bracco Rubidium-Infusion-System Patents

    Bracco had alleged that Jubilant’s RUBY-FILL® Generator and RUBY Rubidium Elution System™ were infringing the two patents in a lawsuit filed in 2018, prompting Jubilant to challenge the validity of the two patents in three Inter Partes Review (“IPR”) proceedings before the U.S. Patent Office. As a result of these favorable rulings, the U.S. Patent Office is expected to cancel all challenged claims of the two Bracco patents.

    This favorable decision from the U.S. Patent Office comes on the heels of another favorable ruling that Jubilant received in December 2019 from the U.S. International Trade Commission (“ITC”), which found three other Bracco patents directed to rubidium infusion systems invalid. The ITC proceeding was instituted in 2018 after Bracco filed a complaint with the ITC accusing Jubilant’s RUBY-FILL Generator and RUBY Rubidium Elution System of infringing the three patents. As a result of the ITC’s invalidity findings, the ITC found Jubilant had not violated section 337 of the Tariff Act of 1930 and terminated the proceeding in Jubilant’s favor.

    “These favorable rulings by the U.S. Patent Office and International Trade Commission further confirm Jubilant’s right to continue development and commercialization of RUBY-FILL in the U.S. marketplace and to continue focusing on our goal of bringing innovative products to the market for patients in need of the latest technology,” stated Pramod Yadav, CEO, Jubilant Pharma Limited.

    Jubilant Radiopharma’s RUBY-FILL Generator and RUBY Rubidium Elution System provide the latest and most advanced technology in PET Rubidium-82 myocardial imaging. RUBY-FILL provides customers a choice in the next generation product, with safety, efficiency, and automation advancements. Jubilant Radiopharma’s products are key in its greater commitment to investing in the growth and expansion of nuclear medicine in the global market.

    For more information on RUBY-FILL and the RUBY Rubidium Elution System’s technology features and benefits, please visit the website at www.RUBY-FILL.com or www.jubilantradiopharma.com.

    ABOUT JUBILANT RADIOPHARMA™: Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Ltd., is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” on a global scale.

    ABOUT JUBILANT PHARMA LIMITED: Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and awholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non- sterile products through 6 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceuti companies globally.

  • 27 January 2020

    Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime®

    Used For the Diagnosis of Intra-Abdominal Infection and Inflammatory Bowel Disease

    YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Limited, announced today that the company received approval from Health Canada for Drax Exametazine® (Kit for the Preparation of Tc99m Exametazime for leukocyte labeling). Leukocyte labeling scintigraphy is a nuclear medicine imaging procedure that helps physicians localize an intra-abdominal infection and inflammatory bowel disease.

    “We are very pleased that Drax Exametazine is now available to patients in Canada,” stated Pramod Yadav, CEO of Jubilant Pharma, Limited “This approval aligns with our core strategy of providing our customers with innovative and differentiated nuclear medicine products used for the diagnosis and treatment of diseases.”

    Drax Exametazime, which is currently approved in the United States, is a radiopharmaceutical used in nuclear medicine (a medical imaging specialty) to help doctors locate infection in a patient when a source of the infection cannot be accurately identified. Identifying the source of the infection is imperative for the proper diagnosis and characterization of disease and a crucial first step in defining a treatment plan for the patient.

    “The Health Canada approval further demonstrates the continued commitment by the Jubilant Radiopharma business to advance the field of nuclear medicine and supports our ongoing mission to improve lives through nuclear medicine,” commented Sergio Calvo, President of Jubilant Radiopharmaceuticals Division. “We remain committed to providing healthcare professionals with the highest quality radiopharmaceuticals and dependable advanced technologies designed to enable better patient outcomes across the globe.”

    ABOUT JUBILANT RADIOPHARMA

    Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Limited, is an industry-leading radiopharmaceutical business focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives through Nuclear Medicine” on a global scale. For more information, click here website

    ABOUT JUBILANT PHARMA LIMITED
    Jubilant Pharma Limited (JPL), a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-sterile products through 5 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more information, visit www.jubilantpharma.com

  • 14 December 2019

    Jubilant Receives Favorable Ruling from the U.S. Courts for RUBY-FILL®

    Yardley, PA, December 11, 2019 – On December 2, 2019, Jubilant DraxImage Inc. and certain of its affiliates (“Jubilant”) received notice of the favorable decision of the U.S. International Trade Commission (the “ITC”) in its case against Bracco Diagnostics Inc. (“Bracco”). The ITC affirmed and upheld, with modification, a final initial determination (FID) of the presiding administrative law judge (ALJ) finding that there was no violation of section 337 of the Tariff Act of 1930, as amended. The ITC has now terminated this investigation.

    This decision in Jubilant’s favor is in response to a complaint filed by Bracco with the ITC in May 2018. Bracco had alleged violations of section 337 of the Tariff Act of 1930 based on importation into the U.S. of certain strontium-rubidium radioisotope infusion systems including, generators by reason of infringement of certain patents. Because of this favorable decision by the full Commission, Jubilant will continue to be able to import its RUBY-FILL® system into the United States.

    “We are extremely pleased with ITC’s decision as it confirms the strength and validity of our intellectual property covering RUBY-FILL, our state-of-the-art technology for PET myocardial perfusion imaging,” stated Pramod Yadav, CEO, Jubilant Pharma Limited. “Our focus continues to be on providing access to innovative products that will improve patient lives through Nuclear Medicine.”

    Jubilant Radiopharma’s RUBY-FILL Generator and RUBY Elution System provide the latest and most advanced technology in PET Rubidium-82 myocardial imaging. Made available in the U.S. market in May 2017, the RUBY-FILL portfolio provides customers a choice of the next generation product, with safety, efficiency, and automation advancements. RUBY-FILL and other Jubilant Radiopharma products are a key part of our greater commitment to investing in the growth and continued advancements of nuclear medicine and, especially, the global cardiac PET market.

    For more information on RUBY-FILL and the RUBY Elution System’s technology features and benefits, please visit the website at www.RUBY-FILL.com or www.jubilantradiopharma.com.

    ABOUT JUBILANT RADIOPHARMA™

    Jubilant Radiopharma, Radiopharmaceutical Division of Jubilant Pharma Limited, is an industry-leading radiopharmaceutical company focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of “Improving Lives Through Nuclear Medicine” on a global scale.

    ABOUT JUBILANT PHARMA LIMITED

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non- sterile products through 5 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio- pharmacies in the US. The Company has a team of over 4,300 multicultural people across the globe and is committed to deliver value to its customers spread

  • 23 July 2019

    Jubilant Cadista Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Drospirenone and Ethinyl Estradiol Tablets, USP, Due to Out-of-Specification Dissolution Test Results

    Company Contact:
    Kevin J. Fortier
    1-800-308-3985
    kevin.fortier@cadista.com

    Salisbury, Maryland, Jubilant Cadista Pharmaceuticals Inc. is voluntarily recalling one lot of Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/ 0.02mg, 28x3 Blister Pack/Carton to the consumer level. The affected product is being recalled due to out-of-specification (OOS) dissolution results at the 3-month stability time point. The affected product is manufactured by Cyndea Pharma, S.L., Olvega (Soria), 42110 Spain under contract from Jubilant Cadista Pharmaceuticals Inc., 207 Kiley Drive Salisbury, Maryland 21801.

    As a result of the OOS dissolution results, product efficacy may be decreased due to incomplete absorption of the active ingredients. To date, Jubilant Cadista Pharmaceuticals Inc. has not received any reports of adverse events related to this recall.

    Product Description: Drospirenone and Ethinyl Estradiol tablets are an estrogen/progestin combination oral contraceptive, indicated for use by women to:

      • Prevent pregnancy
      • Treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraceptio
      • Treat moderate acne for women at least 14 years old and/or if the patient desires an oral contraceptive for birth control

    Drospirenone and Ethinyl Estradiol tablets are packaged into a carton containing 3 blister cards. Each blister card contains 28-film coated, biconvex tablets, in the following order: 24 active pink-color round, unscored, film-coated tablets debossed with a “20” on one side, each containing 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol,  and four (4) inert white-color round, unscored, film-coated tablets debossed with a “PL”.

    The affected Drospirenone and Ethinyl Estradiol Tablets, USP, has been identified as Lot number 183222, with NDC number 59746-763-43 and expiration date of 11/2020.

    Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.02 mg, lot 183222 was distributed Nationwide to wholesalers, distributors, and retailers.

    Jubilant Cadista Pharmaceuticals Inc. is notifying its customers by emailing a recall notification letter and response form and is arranging for return of all recalled product.
    Patients that have used the affected lot of Drospirenone and Ethinyl Estradiol Tablets, USP, 3 mg/0.02 mg should consult their healthcare provider. Patients may return the affected lot to their place of purchase.

    Wholesalers, distributors, and retailers should immediately examine their inventory for the affected lot. All inventory of the affected lot should be quarantined to prevent further distribution to patients.  Customers who purchased the impacted product directly from Jubilant Cadista Pharmaceuticals Inc. can call Inmar at 1-855-205-9246 (9:00 a.m. – 5:00 p.m. EDT, Monday – Friday) to arrange for their return.

    Consumers with additional questions regarding the recall may contact Jubilant Cadista by phone at 1-800-308-3985 (9:00 a.m. – 6:00 p.m. EDT, Monday – Friday). Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

      • Complete and submit the report Online: www.fda.gov/medwatch/report.htm
      • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to
    1-800-FDA-0178

    This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

  • 15 May 2018

    Jubilant receives ANDA approval for Niacin Extended-Release Tablets USP

    Noida (UP), India, Tuesday, May 15, 2018

    Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg, the generic version of Niaspan® of AbbVie, which is indicated to reduce elevated TC, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia thereby reducing the risk of recurrent nonfatal myocardial infarction in patients with a history of myocardial infarction and hyperlipidemia.

    This is the first approval that we have received from the USFDA during the current financial year. As on March 31, 2018, Jubilant had a total of 94 ANDAs for Oral Solids filed in the US, of which 59 had been approved and 12 Sterile (Injectables & Ophthlamics) filings, of which 10 had been approved.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada and a network of over 50 radio-pharmacies in the US. The Company has a team of around 4,300 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

  • 09 February 2018

    Jubilant receives ANDA approval for Amantadine Hydrochloride Tablets

    Noida (UP), India, Friday, February 9, 2018

    Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Amantadine Hydrochloride Tablets, 100 mg, the generic version of Symmetrel® of Endo, which is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. It is also indicated in the treatment of Parkinsonism and drug-induced extrapyramidal reactions.

    This is the ninth approval that we have received from the USFDA during the current financial year. As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US, of which 56 had been approved and 12 Injectable filings, of which 10 had been approved.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada. The Company has a team of around 3,500 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

  • 30 January 2018

    Jubilant receives ANDA approval for Clonidine Hydrochloride Extended-Release Tablets

    Noida (UP), India, Tuesday, January 30, 2018

    Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg, the generic version of Kapvay® of Concordia, which is used for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

    This is the eighth approval that we have received from the USFDA during the current financial year. As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US, of which 56 had been approved and 12 Injectable filings, of which 10 had been approved.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada. The Company has a team of around 3,500 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

  • 28 December 2017

    Jubilant receives sNDA approval for new indications from USFDA for DRAXIMAGE® DTPA

    Noida (UP), India, Thursday, December 28, 2017:Jubilant Life Sciences Limited, an integrated global Pharmaceutical and Life Sciences Company, has announced that Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received a Supplemental New Drug Application (sNDA) approval from USFDA for DRAXIMAGE® DTPA (Kit for the Preparation of Technetium Tc99m Pentetate Injection) powder for solution.

    Specifically, DRAXIMAGE® DTPA is a kit for the preparation of Technetium Tc99m pentetate injection. Technetium Tc99m pentetate is a radioactive diagnostic agent indicated for:

    • Brain imaging in adults
    • Renal visualization, assessment of renal perfusion and estimation of glomerular filtration rate in adult and pediatric patients
    • Lung ventilation imaging and evaluation of pulmonary embolism, when paired with perfusion imaging in adult and pediatric patients when administered by nebulizer for inhalation.

    The expanded labeling incorporates a new route of administration and new indication which enhances the broad utility of DRAXIMAGE® DTPA to include clinical applications to image and diagnose key functional aspects of the pulmonary system, and will allow physicians to perform lung ventilation studies for a much larger patient population suffering from compromised pulmonary function. The product is immediately available in the US market.

    Commenting on the occasion, Mr Shyam S Bhartia, Chairman, and Mr Hari S Bhartia, Co- Chairman and Managing Director, said: “We are very pleased with the latest approval from US FDA for DRAXIMAGE® DTPA. It reinforces our commitment to continued investment in innovation, research and development. Our goal is to bring value to products that enable physicians to deliver high quality diagnostics imaging studies”

    About Jubilant Life Sciences Limited

    Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products Jubilant Life Sciences Limited. 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubl.com through 6 USFDA approved manufacturing facilities in India, USA and Canada and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

  • 29 September 2017

    Jubilant receives approval from Health Canada for the RUBY Elution System™ (RbES) and proprietary RUBY™ Consumable Accessories

    Noida (UP), India, Friday, September 29, 2017

    Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has received approval from Health Canada for its state-of-the-art RUBY Elution System (RbES) and the proprietary RUBY consumable accessories for use with the already approved RUBY-FILL® Rubidium-82 Generator for Positron Emission Tomography of the myocardium.

    RUBY-FILL® is a closed system used to produce a personalized patient dose of rubidium (Rb-82) chloride injection for intravenous use. Rubidium (Rb-82) chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada. The Company has a team of over 3,400 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

  • 01 September 2017

    Jubilant completes acquisition of Radiopharmacy business of Triad

    Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has successfully completed today the acquisition of the US radiopharmacy business of Triad Isotopes, Inc.

    Speaking on the occasion, Mr. Shyam S Bhartia, Chairman and Managing Director, and Mr. Hari S Bhartia, Director, said:

    “The acquisition adds significant scale to our niche Radiopharmaceutical business in the Specialty Pharma - Injectibles segment complementing our strategy of being a leading nuclear medicine player. Triad has an experienced management team, customer focus and strong relationships with GPOs in the United States, which allows us to directly serve customers through hospitals with high quality radiopharmaceutical products. We plan to expand the sales coverage to better and more optimally serve patients, physicians, imaging centers and hospitals, going forward.”

    This acquisition is funded through JPL’s internal accruals with no increase in debt for Jubilant Life Sciences Limited. Triad recorded revenues in excess of US$ 225 Million in CY2016 with positive EBITDA and the acquisition is likely to be earnings accretive. Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies. The acquired radiopharmacies will continue to operate independently under the brand name of ‘Triad Isotopes’. The acquisition is a strategic fit to our niche nuclear medicine business and will provide Jubilant with direct access to hospital networks with ability to deliver more than 3 Million patient doses annually through approximately 1,700 customers. The company intends to maintain and expand Triad’s distribution network.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada. The Company has a team of over 3,400 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

  • 05 May 2017

    JPL - Triad Acquisition - 05.05.2017

  • 25 April 2017

    JPL SGX intimation - 25.04.2017

  • 04 January 2017

    Jubilant announces signing of long term contracts in Radiopharma business

    Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that its wholly own subsidiary Jubilant Pharma Limited, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017.

    Commenting on the occasion, Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co- Chairman and Managing Director, Jubilant Life Sciences Limited said: “We are delighted to announce signing of long term contracts by our Jubilant Draximage business where we are the leader in some of the key products in the US market. These contracts provide visibility on our future revenues with the differentiated and niche products in our Specialty Pharma business and will strengthen the company for its growth, going forward.”

    About Jubilant Life Sciences Limited

    Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

  • 15 November 2016

    Intimation Submitted to Stock Exchanges - 15 November, 2016

  • 13 October 2016

    Disclsoure - October 13, 2016

  • 03 October 2016

    Intimation to NSE BSE - 03 October 2016

  • 15 March 2010

    HollisterStier Contract Manufacturing and Draxis Pharma complete successful FDA, PMDA and HC audits

    Spokane, Washington, U.S.A. March 15, 2010 - Jubilant Organosys, a leading integrated pharma and life sciences company headquartered in India, announced today that two of its contract manufacturing facilities in North America successfully completed regulatory authority cGMP audits, recently. HollisterStier Contract Manufacturing, based in Spokane Washington, U.S.A, completed a successful audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the review of a sterile injectable client product. Draxis Pharma, based in Montreal, Quebec, Canada, also completed a successful audit by the US Food and Drug Administration (FDA) and Health Canada.

    HollisterStier

    The audit by the Japanese Pharmaceutical and Medical Device Agency (PMDA) revealed no significant observations, which has resulted in a recommendation to the MHLW that Hollister-Stier be listed as an approved manufacturing site for the client's product. Independent of the PMDA audit, the HollisterStier facility was also recently approved by the European Medicines Agency (EMA) as a manufacturing site for this same product.

    Draxis Pharma

    The audit of Draxis Pharma by the US Food and Drug Administration (FDA) included a comprehensive cGMP review of both sterile parenteral and non-sterile semi-solid manufacturing capabilities and a Pre-Approval Inspection for three client products. No observations were received from this audit. Recommendations for site approvals for the three new client products are expected. The audit of Draxis Pharma by Health Canada focused on a cGMP review of a dedicated packaging capability and revealed no significant audit observations.

    Marcelo Morales, CEO of HollisterStier Contract Manufacturing and Draxis Pharma, said "We are extremely pleased with the audit findings at both our HollisterStier and Draxis Pharma facilities. Maintaining a rigorous quality culture and robust quality systems, combined with effectively managing our clients' projects, assures the success of these projects in the global market place."

    About Jubilant Organosys

    Jubilant Organosys Limited., an integrated pharmaceutical industry player, is the largest custom research and manufacturing services (CRAMS) out of India. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-sterile products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, Life Science Chemicals, Nutrition Ingredients and Health Care. The Company also manufactures Agri and Performance Polymer products. For more information please visit : www.jubl.com

    About HollisterStier Contract Manufacturing and DRAXIS Pharma

    HollisterStier Contract Manufacturing and DRAXIS Pharma are separately branded contract manufacturing organizations that joined capabilities and services under the ownership of Jubilant Organosys. HollisterStier is a global manufacturing service provider, able to aseptically fill liquid and lyophilized products at their Spokane, Washington, U.S.A., facility and DRAXIS Pharma offers manufacturing services for sterile liquid and sterile and non-sterile semi-solid dosage forms at their Montreal, Quebec, Canada, facility. Manufacturing facilities for solid dosage forms are also available in the United States and India through HollisterStier and DRAXIS.

     Both organizations offer highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. HollisterStier and DRAXIS are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities. For more information about HollisterStier Contract Manufacturing, please visit HScontract.com and for more information about DRAXIS Pharma, visit www.DRAXISPharma.com.

    HollisterStier-Draxis Pharma
    Media Inquiries:
    Shannon Jordan
    509.482.4958

  • 10 June 2008

    HollisterStier Laboratories LLC and DRAXIS Specialty Pharmaceuticals

    UTTAR PRADESH, India, October 6, 2008- Jubilant Organosys Limited, parent company to HollisterStier Laboratories and DRAXIS Specialty Pharmaceuticals, is pleased to announce the strategic alignment of the organizations.

    Both HollisterStier and Draxis are leaders in the manufacturing services and specialty pharmaceutical products industries and, together with Jubilant, have outlined a cohesive operating strategy that will leverage the capabilities of the organizations. Jubilant has put in place a leadership team to spearhead this alignment which is aimed to broaden the capacity, capability and services offered to clients.

    Marcelo Morales has been named Chief Executive Officer for the Contract Manufacturing organizations that will be inclusive of the sterile injectables manufacturing arm of HollisterStier and the sterile and non-sterile manufacturing operation of DRAXIS.

    DRAXIS' current Chief Executive Officer, Jean Pierre Robert, has been named CEO for the Specialty Pharmaceutical organization, under which the well established imaging technologies of DRAXIS and Allergy Therapeutics of HollisterStier will fall.

    "These changes are expected to result in exciting opportunities for our combined organizations as well as our clients," said Jubilant Organosys Chairman & Managing Director, Shyam Bhartia. "Providing continued innovation and expanding our breadth of services and locations helps us ensure that our customers receive the level of quality, flexibility and expertise that the market demands."

    About Jubilant Organosys Limited

    Jubilant Organosys Limited is an integrated pharmaceutical industry player and is one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and Health Care. Headquartered in India, the company has more than 4,300 employees across organizations in India, North America, Europe and China, with four manufacturing locations in India, one in Canada and two in the United States. For more information about Jubilant Organosys Limited, visit : www.jubl.com.

    About HollisterStier Laboratories

    HollisterStier Laboratories LLC provides a complete range of services to support the pharmaceutical and biopharmaceutical industries. HollisterStier's Contract Manufacturing division provides state-of-the-art clinical through commercial aseptic liquid fill/finish and lyophilization services to global markets.

    HollisterStier Allergy Therapeutics is a worldwide leader in the manufacture of allergenic extracts, targeted primarily at treating allergies and asthma. HollisterStier is owned by Jubilant Organosys Limited and is based in Spokane, Washington, USA. For further information about HollisterStier Laboratories, visit : www.hollisterstier.com.

    About DRAXIS Health Inc.

    DRAXIS Health Inc., through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc. (DSPI), provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and sterile creams. Non-sterile products are produced as solid oral dosage forms (tablets and capsules) and as semi-solid dosage forms (ointments and creams). Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division of DSPI and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division of DSPI. Consolidated operations are located in Montreal, Canada. For more information about DRAXIS, visit : www.draxis.com.

    where can you buy the abortion pill

    order abortion pill medical abortion pill online

    where can you buy the abortion pill

    an abortion pill medical abortion pill online

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.